Skip to main content
SpringerLink
Log in

Sarcoglycanopathies: Clinical, Molecular and Genetic Characteristics, Epidemiology, Diagnostics and Treatment Options

  • Reviews and Theoretical Articles
  • Published:
Russian Journal of Genetics Aims and scope Submit manuscript

Abstract

Sarcoglycanopathies are a group of autosomal recessive limb-girdle muscular dystrophies (LGMD) caused by mutations in sarcoglycan genes: SGCA (LGMD 2D, MIM 600119), SGCB (LGMD 2E, MIM 604286), SGCG (LGMD 2C, MIM 353700), and SGCD (LGMD 2F, MIM 601287). These genes encode four transmembrane sarcoglycan subunits participating in formation of the large sarcolemmal dystrophin- glycoprotein complex. Clinical symptoms of sarcoglycanopathies resemble the ones in Duchenne/Becker muscular dystrophy and several autosomal recessive LGMD, which causes difficulties in the differential diagnostics between these diseases. This review covers the main aspects of sarcoglycanopathies, such as etiology, spectrum of mutations, clinical features and diagnostics. In addition, we review the fundamental pathogenesis mechanisms leading to sarcoglycanopathies, which can also help to understand the potential options for treatment for patients with muscular dystrophies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meryon, E., On granular and fatty degeneration of the voluntary muscles, Med. Chir. Trans., 1852, vol. 35, pp. 73.1–84.1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Duchenne, G., Recherches sur la paralysie musculaire pseudohypertrophique en paralysie myosclerosique, Arch. Gen. Med., 1868, vol. 11, pp. 5–25.

    Google Scholar 

  3. Kloepfer, H.W. and Talley, C., Autosomal recessive inheritance of Duchenne-type muscular dystrophy, Ann. Hum. Genet., 1958, vol. 22, no. 2, pp. 138–143.

    Article  CAS  PubMed  Google Scholar 

  4. Koenig, M., Hoffman, E.P., Bertelson, C.J., et al., Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and reliminary genomic organization of the DMD gene in normal and affected individuals, Cell, 1987, vol. 50, no. 3, pp. 509–517.

    Article  CAS  PubMed  Google Scholar 

  5. Hoffman, E.P., Brown, R.H., Jr., and Kunkel, L.M., Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 1987, vol. 51, no. 6, pp. 919–928.

    Article  CAS  PubMed  Google Scholar 

  6. Yoshida, M., Suzuki, A., Yamamoto, H., et al., Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-Dglucoside, Eur. J. Biochem., 1994, vol. 222, no. 3, pp. 1055–1061.

    Article  CAS  PubMed  Google Scholar 

  7. Ben Othmane, K., Ben Hamida, M., Pericak-Vance, M.A., et al., Linkage of Tunisian autosomal recessive Duchenne-like muscular dystrophy to the pericentromeric region of chromosome 13q, Nat. Genet., 1992, vol. 2, no. 4, pp. 315–317.

    Article  PubMed  Google Scholar 

  8. Bushby, K.M. and Beckmann, J.S., The limb—girdle muscular dystrophies—proposal for a new nomenclature, Neuromuscular Disord., 1995, vol. 5, no. 4, pp. 337–343.

    Article  CAS  Google Scholar 

  9. Richard, I., Broux, O., Allamand, V., et al., Mutations in the proteolytic enzyme calpain 3 cause limb—girdle muscular dystrophy type 2A, Cell, 1995, vol. 81, no. 1, pp. 27–40.

    Article  CAS  PubMed  Google Scholar 

  10. Bashir, R., Keers, S., Strachan, T., et al., Genetic and physical mapping at the limb—girdle muscular dystrophy locus (LGMD2B) on chromosome 2p, Genomics, 1996, vol. 33, no. 1, pp. 46–52.

    Article  CAS  PubMed  Google Scholar 

  11. Roberds, S.L., Anderson, R.D., Ibraghimov-Beskrovnaya, O., and Campbell, K.P., Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin), J. Biol. Chem., 1993, vol. 268, no. 32, pp. 23739–23742.

    CAS  PubMed  Google Scholar 

  12. Lim, L.E., Duclos, F., Broux, O., et al., Beta-sarcoglycan: characterization and role in limb—girdle muscular dystrophy linked to 4q12, Nat. Genet., 1995, vol. 11, no. 3, pp. 257–265.

    Article  CAS  PubMed  Google Scholar 

  13. Noguchi, S., McNally, E.M., Ben Othmane, K., et al., Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy, Science, 1995, vol. 270, no. 5237, pp. 819–822.

    Article  CAS  PubMed  Google Scholar 

  14. Passos-Bueno, M.R., Moreira, E.S., Vainzof, M., et al., Linkage analysis in autosomal recessive limb— girdle muscular dystrophy (AR LGMD) maps a sixth form to 5q33-34 (LGMD2F) and indicates that there is at least one more subtype of AR LGMD, Hum. Mol. Genet., 1996, vol. 5, no. 6, pp. 815–820.

    Article  CAS  PubMed  Google Scholar 

  15. Nigro, V., Piluso, G., Belsito, A., et al., Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein, Hum. Mol. Genet., 1996, vol. 5, no. 8, pp. 1179–1186.

    Article  CAS  PubMed  Google Scholar 

  16. Bonnemann, C.G., Modi, R., Noguchi, S., et al., Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex, Nat. Genet., 1995, vol. 11, no. 3, pp. 266–273.

    Article  CAS  PubMed  Google Scholar 

  17. Nigro, V., de Sa Moreira, E., Piluso, G., et al., Autosomal recessive limb—girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene, Nat. Genet., 1996, vol. 14, no. 2, pp. 195–198.

    Article  CAS  PubMed  Google Scholar 

  18. Roberds, S.L., Leturcq, F., Allamand, V., et al., Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy, Cell, 1994, vol. 78, no. 4, pp. 625–633.

    Article  CAS  PubMed  Google Scholar 

  19. Ettinger, A.J., Feng, G., and Sanes, J.R. Epsilon-sarcoglycan, a broadly expressed homologue of the gene mutated in limb—girdle muscular dystrophy 2D, J. Biol. Chem., 1997, vol. 272, no. 51, pp. 32534–32538.

    Article  CAS  PubMed  Google Scholar 

  20. Wheeler, M.T., Zarnegar, S., and McNally, E.M. Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy, Hum. Mol. Genet., 2002, vol. 11, no. 18, pp. 2147–2154.

    Article  CAS  PubMed  Google Scholar 

  21. Chen, J., Shi, W., Zhang, Y., et al., Identification of functional domains in sarcoglycans essential for their interaction and plasma membrane targeting, Exp. Cell Res., 2006, vol. 312, no. 9, pp. 1610–1625. doi 10.1016/j.yexcr.2006.01.024

    Article  CAS  PubMed  Google Scholar 

  22. Shiga, K., Yoshioka, H., Matsumiya, T., et al., Zetasarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of the sarcoglycan complex, Exp. Cell Res., 2006, vol. 312, no. 11, pp. 2083–2092.

    Article  CAS  PubMed  Google Scholar 

  23. Chan, Y.M., Bonnemann, C.G., Lidov, H.G., and Kunkel, L.M. Molecular organization of sarcoglycan complex in mouse myotubes in culture, J. Cell Biol., 1998, vol. 143, no. 7, pp. 2033–2044.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dickens, N.J., Beatson, S., and Ponting, C.P. Cadherin-like domains in alpha-dystroglycan, alpha/epsilon-sarcoglycan and yeast and bacterial proteins, Curr. Biol., 2002, vol. 12, no. 6, pp. R197–R199.

    Article  CAS  PubMed  Google Scholar 

  25. Betto, R., Senter, L., Ceoldo, S., et al., Ecto-ATPase activity of alpha-sarcoglycan (adhalin), J. Biol. Chem., 1999, vol. 274, no. 12, pp. 7907–7912.

    Article  CAS  PubMed  Google Scholar 

  26. Hack, A.A., Groh, M.E., and McNally, E.M. Sarcoglycans in muscular dystrophy, Microsc. Res. Tech., 2000, vol. 48, nos. 3–4, pp. 167–180. doi 10.1002/(sici)1097-0029(20000201/15)48:3/4<167::aidjemt5> 3.0.co;2-t

    Article  CAS  PubMed  Google Scholar 

  27. McNally, E.M., Duggan, D., Gorospe, J.R., et al., Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy, Hum. Mol. Genet., 1996, vol. 5, no. 11, pp. 1841–1847.

    Article  CAS  PubMed  Google Scholar 

  28. Hegde, R.S. and Kang, S.W., The concept of translocational regulation, J. Cell Biol., 2008, vol. 182, no. 2, pp. 225–232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hebert, D.N. and Molinari, M., In and out of the ER: protein folding, quality control, degradation, and related human diseases, Physiol. Rev., 2007, vol. 87, no. 4, pp. 1377–1408.

    CAS  PubMed  Google Scholar 

  30. Anelli, T. and Sitia, R., Protein quality control in the early secretory pathway, Embo J., 2008, vol. 27, no. 2, pp. 315–327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Holt, K.H. and Campbell, K.P., Assembly of the sarcoglycan complex: insights for muscular dystrophy, J. Biol. Chem., 1998, vol. 273, no. 52, pp. 34667–34670.

    Article  CAS  PubMed  Google Scholar 

  32. Noguchi, S., Wakabayashi, E., Imamura, M., et al., Formation of sarcoglycan complex with differentiation in cultured myocytes, Eur. J. Biochem., 2000, vol. 267, no. 3, pp. 640–648.

    Article  CAS  PubMed  Google Scholar 

  33. Draviam, R.A., Shand, S.H., and Watkins, S.C. The beta-delta-core of sarcoglycan is essential for deposition at the plasma membrane, Muscle Nerve, 2006, vol. 34, no. 6, pp. 691–701.

    Article  CAS  PubMed  Google Scholar 

  34. Hack, A.A., Lam, M.Y., Cordier, L., et al., Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin–glycoprotein complex, J. Cell Sci., 2000, vol. 113. no. 14, pp. 2535–2544.

    CAS  PubMed  Google Scholar 

  35. Allikian, M.J. and McNally, E.M., Processing and assembly of the dystrophin glycoprotein complex, Traffic, 2007, vol. 8, no. 3, pp. 177–183.

    Article  CAS  PubMed  Google Scholar 

  36. Ozawa, E., Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era, Proc. Jpn. Acad., Ser. B, 2010, vol. 86, no. 8, pp. 798–821.

    Article  CAS  Google Scholar 

  37. Ervasti, J.M., Dystrophin, its interactions with other proteins, and implications for muscular dystrophy, Biochim. Biophys. Acta, 2007, vol. 2, pp. 108–117.

    Google Scholar 

  38. Petrof, B.J., Shrager, J.B., Stedman, H.H., et al., Dystrophin protects the sarcolemma from stresses developed during muscle contraction, Proc. Natl. Acad. Sci. U.S.A., 1993, vol. 90, no. 8, pp. 3710–3714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Crosbie, R.H., Lim, L.E., Moore, S.A., et al., Molecular and genetic characterization of sarcospan: insights into sarcoglycan—sarcospan interactions, Hum. Mol. Genet., 2000, vol. 9, no. 13, pp. 2019–2027.

    Article  CAS  PubMed  Google Scholar 

  40. Brenman, J.E., Chao, D.S., Xia, H., et al., Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy, Cell, 1995, vol. 82, no. 5, pp. 743752.

    Article  Google Scholar 

  41. Yoshida, M., Hama, H., Ishikawa-Sakurai, M., et al., Biochemical evidence for association of dystrobrevin with the sarcoglycan–sarcospan complex as a basis for understanding sarcoglycanopathy, Hum. Mol. Genet., 2000, vol. 9, no. 7, pp. 1033–1040.

    Article  CAS  PubMed  Google Scholar 

  42. Davies, K.E. and Nowak, K.J., Molecular mechanisms of muscular dystrophies: old and new players, Nat. Rev. Mol. Cell Biol., 2006, vol. 7, no. 10, pp. 762773.

    Article  CAS  Google Scholar 

  43. Lapidos, K.A., Kakkar, R., and McNally, E.M. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma, Circ. Res., 2004, vol. 94, no. 8, pp. 1023–1031.

    Article  CAS  PubMed  Google Scholar 

  44. Thompson, T.G., Chan, Y.M., Hack, A.A., et al., Filamin 2 (FLN2): a muscle-specific sarcoglycan interacting protein, J. Cell Biol., 2000, vol. 148, no. 1, pp. 115–126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Yoshida, T., Pan, Y., Hanada, H., et al., Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes, J. Biol. Chem., 1998, vol. 273, no. 3, pp. 1583–1590.

    Article  CAS  PubMed  Google Scholar 

  46. Sandona, D., Danieli-Betto, D., Germinario, E., et al., The T-tubule membrane ATP-operated P2X4 receptor influences contractility of skeletal muscle, Faseb J., 2005, vol. 19, no. 9, pp. 1184–1186.

    Article  CAS  PubMed  Google Scholar 

  47. Li, D., Long, C., Yue, Y., and Duan, D. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice, Hum. Mol. Genet., 2009, vol. 18, no. 7, pp. 1209–1220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Zimprich, A., Grabowski, M., Asmus, F., et al., Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus—dystonia syndrome, Nat. Genet., 2001, vol. 29, no. 1, pp. 66–69.

    Article  CAS  PubMed  Google Scholar 

  49. Loo, T.W. and Clarke, D.M., Chemical and pharmacological chaperones as new therapeutic agents, Expert Rev. Mol. Med., 2007, vol. 9, no. 16, pp. 1–18.

    Article  PubMed  Google Scholar 

  50. Guglieri, M., Magri, F., D’Angelo, M.G., et al., Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients, Hum. Mutat., 2008, vol. 29, no. 2, pp. 258–266.

    Article  CAS  PubMed  Google Scholar 

  51. McNally, E.M., Yoshida, M., Mizuno, Y., et al., Human adhalin is alternatively spliced and the gene is located on chromosome 17q21, Proc. Natl. Acad. Sci. U.S.A., 1994, vol. 91, no. 21, pp. 9690–9694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Trabelsi, M., Kavian, N., Daoud, F., et al., Revised spectrum of mutations in sarcoglycanopathies, Eur. J. Hum. Genet., 2008, vol. 16, no. 7, pp. 793–803. doi 10.1038/ejhg.2008.9

    Article  CAS  PubMed  Google Scholar 

  53. Moreira, E.S., Vainzof, M., Suzuki, O.T., et al., Genotype— phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations, J. Med. Genet., 2003, vol. 40, no. 2, p. E12.

    Google Scholar 

  54. Hackman, P., Juvonen, V., Sarparanta, J., et al., Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients, Muscle Nerve, 2005, vol. 31, no. 2, pp. 199–204.

    Article  CAS  PubMed  Google Scholar 

  55. Carrie, A., Piccolo, F., Leturcq, F., et al., Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D), J. Med. Genet., 1997, vol. 34, no. 6, pp. 470–475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Tetreault, M., Srour, M., Allyson, J., et al., Founder mutation for alpha-sarcoglycan-LGMD2D in a Magdalen Islands Acadian cluster, Can. J. Neurol. Sci., 2011, vol. 38, no. 5, pp. 747–752.

    Article  CAS  PubMed  Google Scholar 

  57. Duggan, D.J., Gorospe, J.R., Fanin, M., et al., Mutations in the sarcoglycan genes in patients with myopathy, N. Engl. J. Med., 1997, vol. 336, no. 9, pp. 618624. doi 10.1056/nejm199702273360904

    Article  Google Scholar 

  58. Kawai, H., Akaike, M., Endo, T., et al., Adhalin gene mutations in patients with autosomal recessive childhood onset muscular dystrophy with adhalin deficiency, J. Clin. Invest., 1995, vol. 96, no. 3, pp. 1202–1207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Bartoli, M., Gicquel, E., Barrault, L., et al., Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation, Hum. Mol. Genet., 2008, vol. 17, no. 9, pp. 1214–1221.

    Article  CAS  PubMed  Google Scholar 

  60. Tarnopolsky, M., Hoffman, E., Giri, M., et al., Alpha-sarcoglycanopathy presenting as exercise intol erance and rhabdomyolysis in two adults, Neuromuscul. Disord., 2015, vol. 25, no. 12, pp. 952–954.

    Article  CAS  PubMed  Google Scholar 

  61. Boito, C., Fanin, M., Siciliano, G., et al., Novel sarcoglycan gene mutations in a large cohort of Italian patients, J. Med. Genet., 2003, vol. 40, no. 5. e67. doi 10.1136/jmg.40.5.e67

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Eymard, B., Romero, N.B., Leturcq, F., et al., Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy, Neurology, 1997, vol. 48, no. 5, pp. 1227–1234.

    CAS  PubMed  Google Scholar 

  63. Piccolo, F., Roberds, S.L., Jeanpierre, M., et al., Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity, Nat. Genet., 1995, vol. 10, no. 2, pp. 243–245.

    Article  CAS  PubMed  Google Scholar 

  64. Bonnemann, C.G., Passos-Bueno, M.R., McNally, E.M., et al., Genomic screening for beta-sarcoglycan gene mutations: missense mutations may cause severe limb—girdle muscular dystrophy type 2E (LGMD 2E), Hum. Mol. Genet., 1996, vol. 5, no. 12, pp. 1953–1961.

    Article  CAS  PubMed  Google Scholar 

  65. Soheili, T., Gicquel, E., Poupiot, J., et al., Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications, Hum. Mutat., 2012, vol. 33, no. 2, pp. 429–439. doi 10.1002/humu.21659

    Article  CAS  PubMed  Google Scholar 

  66. Duclos, F., Broux, O., Bourg, N., et al., Beta-sarcoglycan: genomic analysis and identification of a novel missense mutation in the LGMD2E Amish isolate, Neuromuscul. Disord., 1998, vol. 8, no. 1, pp. 30–38.

    Article  CAS  PubMed  Google Scholar 

  67. Klinge, L., Dekomien, G., Aboumousa, A., et al., Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?, Neuromuscul. Disord., 2008, vol. 18, no. 12, pp. 934–941.

    Article  PubMed  Google Scholar 

  68. McNally, E.M., Passos-Bueno, M.R., Bonnemann, C.G., et al., Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation, Am. J. Hum. Genet., 1996, vol. 59, no. 5, pp. 1040–1047.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Piccolo, F., Jeanpierre, M., Leturcq, F., et al., A founder mutation in the gamma-sarcoglycan gene of gypsies possibly predating their migration out of India, Hum. Mol. Genet., 1996, vol. 5, no. 12, pp. 2019–2022.

    Article  CAS  PubMed  Google Scholar 

  70. Todorova, A., Ashikov, A., Beltcheva, O., et al., C283Y mutation and other C-terminal nucleotide changes in the gamma-sarcoglycan gene in the Bulgarian Gypsy population, Hum. Mutat., 1999, vol. 14, no. 1, pp. 40–44.

    Article  CAS  PubMed  Google Scholar 

  71. Morar, B., Gresham, D., Angelicheva, D., et al., Mutation History of the Roma/Gypsies, Am. J. Hum. Genet., 2004, vol. 75, no. 4, pp. 596–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Khadilkar, S.V., Singh, R.K., Hegde, M., et al., Spectrum of mutations in sarcoglycan genes in the Mumbai region of western India: high prevalence of 525delT, Neurol. India, 2009, vol. 57, no. 4, pp. 406–410. doi 10.4103/0028-3886.55603

    Article  PubMed  Google Scholar 

  73. El Kerch, F., Ratbi, I., Sbiti, A., et al., Carrier frequency of the c.525delT mutation in the SGCG gene and estimated prevalence of limb girdle muscular dystrophy type 2C among the Moroccan population, Genet. Test Mol. Biomarkers, 2014, vol. 18, no. 4, pp. 253–256. doi 10.1089/gtmb.2013.0326

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Jung, D., Duclos, F., Apostol, B., et al., Characterization of delta-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb—girdle muscular dystrophy, J. Biol. Chem., 1996, vol. 271, no. 50, pp. 32321–32329.

    Article  CAS  PubMed  Google Scholar 

  75. Vainzof, M., Passos-Bueno, M.R., Canovas, M., et al., The sarcoglycan complex in the six autosomal recessive limb—girdle muscular dystrophies, Hum. Mol. Genet., 1996, vol. 5, no. 12, pp. 1963–1969.

    Article  CAS  PubMed  Google Scholar 

  76. Campbell, M.D., Witcher, M., Gopal, A., and Michele, D.E. Dilated cardiomyopathy mutations in delta-sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability, Am. J. Physiol.: Heart Circ. Physiol., 2016, vol. 310, no. 9, p. 11.

    Google Scholar 

  77. Karkkainen, S., Miettinen, R., Tuomainen, P., et al., A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy, J. Mol. Med., 2003, vol. 81, no. 12, pp. 795–800.

    Article  PubMed  CAS  Google Scholar 

  78. Heydemann, A., Demonbreun, A., Hadhazy, M., et al., Nuclear sequestration of delta-sarcoglycan disrupts the nuclear localization of lamin A/C and emerin in cardiomyocytes, Hum. Mol. Genet., 2007, vol. 16, no. 4, pp. 355–363.

    Article  CAS  PubMed  Google Scholar 

  79. Bauer, R., Hudson, J., Muller, H.D., et al., Does delta-sarcoglycan-associated autosomal-dominant cardiomyopathy exist?, Eur. J. Hum. Genet., 2009, vol. 17, no. 9, pp. 1148–1153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Chen, J., Jin, Y., Wang, H., et al., A haplotype of two novel polymorphisms in delta-sarcoglycan gene increases risk of dilated cardiomyopathy in mongoloid population, PLoS One, 2015, vol. 10, no. 12. e0145602. doi 10.1371/journal.pone.0145602

    Google Scholar 

  81. Schade van Westrum, S.M., Dekker, L.R., de Voogt, W.G., et al., Cardiac involvement in Dutch patients with sarcoglycanopathy: a cross-sectional cohort and follow-up study, Muscle Nerve, 2014, vol. 50, no. 6, pp. 909–913. doi 10.1002/mus.24233

    Article  PubMed  Google Scholar 

  82. Semplicini, C., Vissing, J., Dahlqvist, J.R., et al., Clinical and genetic spectrum in limb—girdle muscular dystrophy type 2E, Neurology, 2015, vol. 84, no. 17, pp. 1772–1781. doi 10.1212/wnl.0000000000001519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Politano, L., Nigro, V., Passamano, L., et al., Evaluation of cardiac and respiratory involvement in sarcoglycanopathies, Neuromuscul. Disord., 2001, vol. 11, no. 2, pp. 178–185.

    Article  CAS  PubMed  Google Scholar 

  84. Pena, L., Kim, K., and Charrow, J. Episodic myoglobinuria in a primary gamma-sarcoglycanopathy, Neuromuscul. Disord., 2010, vol. 20, no. 5, pp. 337–339. doi 10.1016/j.nmd.2010.02.015

    Article  PubMed  Google Scholar 

  85. Ceravolo, F., Messina, S., Rodolico, C., et al., Myoglobinuria as first clinical sign of a primary alpha-sarcoglycanopathy, Eur. J. Pediatr., 2014, vol. 173, no. 2, pp. 239–242. doi 10.1007/s00431-013-2151-z

    Article  CAS  PubMed  Google Scholar 

  86. Walter, M.C., Dekomien, G., Schlotter-Weigel, B., et al., Respiratory insufficiency as a presenting symptom of LGMD2D in adulthood, Acta Myol., 2004, vol. 23, no. 1, pp. 1–5.

    CAS  PubMed  Google Scholar 

  87. Fayssoil, A., Drouet, T., Luis, D., et al., Acute ischemic stroke in gamma-sarcoglycanopathy, Presse Med., 2013, vol. 42, no. 4, part 1, pp. 484–486. doi 10.1016/j.lpm.2012.07.022

    Article  PubMed  Google Scholar 

  88. Norwood, F.L.M., Harling, C., Chinnery, P.F., et al., Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population, Brain, 2009, vol. 132, no. 11, pp. 3175–3186. doi 10.1093/brain/awp236

    Article  PubMed  PubMed Central  Google Scholar 

  89. Fanin, M., Duggan, D.J., Mostacciuolo, M.L., et al., Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations, J. Med. Genet., 1997, vol. 34, no. 12, pp. 973–977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Moore, S.A., Shilling, C.J., Westra, S., et al., Limb— girdle muscular dystrophy in the United States, J. Neuropathol. Exp. Neurol., 2006, vol. 65, no. 10, pp. 995–1003.

    Article  PubMed  Google Scholar 

  91. Meena, A.K., Sreenivas, D., Sundaram, C., et al., Sarcoglycanopathies: a clinico-pathological study, Neurol. India, 2007, vol. 55, no. 2, pp. 117–121.

    Article  CAS  PubMed  Google Scholar 

  92. Gomez-Diaz, B., Rosas-Vargas, H., Roque-Ramirez, B., et al., Immunodetection analysis of muscular dystrophies in Mexico, Muscle Nerve, 2012, vol. 45, no. 3, pp. 338–345. doi 10.1002/mus.22314

    Article  PubMed  Google Scholar 

  93. Gouveia, T.L., Paim, J.F., Pavanello, R.C., et al., Sarcoglycanopathies: a multiplex molecular analysis for the most common mutations, Diagn. Mol. Pathol., 2006, vol. 15, no. 2, pp. 95–100.

    Article  CAS  PubMed  Google Scholar 

  94. Vainzof, M., Passos-Bueno, M.R., Pavanello, R.C., et al., Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb—girdle muscular dystrophy in the Brazilian population, J. Neurol. Sci., 1999, vol. 164, no. 1, pp. 44–49.

    Article  CAS  PubMed  Google Scholar 

  95. Ginjaar, H.B., van der Kooi, A.J., Ceelie, H., et al., Sarcoglycanopathies in Dutch patients with autosomal recessive limb girdle muscular dystrophy, J. Neurol., 2000, vol. 247, no. 7, pp. 524–529.

    Article  CAS  PubMed  Google Scholar 

  96. Stehlikova, K., Skalova, D., Zidkova, J., et al., Autosomal recessive limb—girdle muscular dystrophies in the Czech Republic, BMC Neurol., 2014, vol. 14, no. 154, pp. 014–0154.

    Google Scholar 

  97. Sveen, M.L., Schwartz, M., and Vissing, J. High prevalence and phenotype—genotype correlations of limb girdle muscular dystrophy type 2I in Denmark, Ann. Neurol., 2006, vol. 59, no. 5, pp. 808–815.

    Article  CAS  PubMed  Google Scholar 

  98. Cotta, A., Carvalho, E., da-Cunha-Junior, A.L., et al., Common recessive limb girdle muscular dystrophies differential diagnosis: why and how?, Arq. Neuropsiquiatr., 2014, vol. 72, no. 9, pp. 721–734.

    Article  PubMed  Google Scholar 

  99. Nalini, A., Gayathri, N., Thaha, F., et al., Sarcoglycanopathy: clinical and histochemical characteristics in 66 patients, Neurol. India, 2010, vol. 58, no. 5, pp. 691–696. doi 10.4103/0028-3886.72164

    Article  CAS  PubMed  Google Scholar 

  100. ten Dam, L., van der Kooi, A.J., van Wattingen, M., et al., Reliability and accuracy of skeletal muscle imaging in limb—girdle muscular dystrophies, Neurology, 2012, vol. 79, no. 16, pp. 1716–1723. doi 10.1212/WNL.0b013e31826e9b73

    Article  PubMed  Google Scholar 

  101. Wicklund, M.P. and Kissel, J.T., The limb—girdle muscular dystrophies, Neurol. Clin., 2014, vol. 32, no. 3, pp. 729–749.

    Article  PubMed  Google Scholar 

  102. Higuchi, I., Kawai, H., Umaki, Y., et al., Different manners of sarcoglycan expression in genetically proven alpha-sarcoglycan deficiency and gamma-sarcoglycan deficiency, Acta Neuropathol., 1998, vol. 96, no. 2, pp. 202–206.

    Article  CAS  PubMed  Google Scholar 

  103. Albuquerque, M.A., Abath-Neto, O., Maximino, J.R., et al., Clinical aspects of patients with sarcoglycanopathies under steroids therapy, Arq. Neuropsiquiatr., 2014, vol. 72, no. 10, pp. 768–772.

    Article  PubMed  Google Scholar 

  104. Angelini, C., Fanin, M., Menegazzo, E., et al., Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb—girdle muscular dystrophy patient, Muscle Nerve, 1998, vol. 21, no. 6, pp. 769–775.

    Article  CAS  PubMed  Google Scholar 

  105. Connolly, A.M., Pestronk, A., Mehta, S., and Al-Lozi, M. Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years, Muscle Nerve, 1998, vol. 21, no. 11, pp. 1549–1553.

    Article  CAS  PubMed  Google Scholar 

  106. Wong-Kisiel, L.C. and Kuntz, N.L., Two siblings with limb—girdle muscular dystrophy type 2E responsive to deflazacort, Neuromuscul. Disord., 2010, vol. 20, no. 2, pp. 122–124.

    Article  PubMed  Google Scholar 

  107. Fisher, I., Abraham, D., Bouri, K., et al., Prednisolone- induced changes in dystrophic skeletal muscle, Faseb J., 2005, vol. 19, no. 7, pp. 834–836.

    Article  CAS  PubMed  Google Scholar 

  108. Tamma, R., Annese, T., Capogrosso, R.F., et al., Effects of prednisolone on the dystrophin-associated proteins in the blood—brain barrier and skeletal muscle of dystrophic mdx mice, Lab. Invest., 2013, vol. 93, no. 5, pp. 592–610.

    Article  CAS  PubMed  Google Scholar 

  109. Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., et al., Sustained alpha-sarcoglycan gene expression after gene transfer in limb—girdle muscular dystrophy, type 2D, Ann. Neurol., 2010, vol. 68, no. 5, pp. 629638. doi 10.1002/ana.22251

    Google Scholar 

  110. Herson, S., Hentati, F., Rigolet, A., et al., A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Brain, 2012, vol. 135, part 2, pp. 483492. doi 10.1093/brain/awr342

    Article  Google Scholar 

  111. Vitiello, C., Faraso, S., Sorrentino, N.C., et al., Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments, PLoS One, 2009, vol. 4, no. 3, p. 31.

    Article  CAS  Google Scholar 

  112. Bianchini, E., Fanin, M., Mamchaoui, K., et al., Unveiling the degradative route of the V247M alphasarcoglycan mutant responsible for LGMD-2D, Hum. Mol. Genet., 2014, vol. 23, no. 14, pp. 3746–3758. doi 10.1093/hmg/ddu088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Sandona, D. and Betto, R., Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects, Expert Rev. Mol. Med., 2009, vol. 11. e28. doi 10.1017/s1462399409001203

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Centre for Medical Genetics, Moscow, 115478, Russia

    M. V. Bulakh, O. P. Ryzhkova & A. V. Polyakov

Authors
  1. M. V. Bulakh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. P. Ryzhkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. Polyakov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. V. Bulakh.

Additional information

Original Russian Text © M.V. Bulakh, O.P. Ryzhkova, A.V. Polyakov, 2018, published in Genetika, 2018, Vol. 54, No. 2, pp. 135–152.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bulakh, M.V., Ryzhkova, O.P. & Polyakov, A.V. Sarcoglycanopathies: Clinical, Molecular and Genetic Characteristics, Epidemiology, Diagnostics and Treatment Options. Russ J Genet 54, 129–144 (2018). https://doi.org/10.1134/S1022795418020059

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1022795418020059

Keywords

Search

Navigation